Waydhas C, Görlinger K
Klinik für Unfallchirurgie, Universitätsklinikum Essen, Hufelandstr. 55, 45147 Essen.
Unfallchirurg. 2009 Nov;112(11):942-50. doi: 10.1007/s00113-009-1681-3.
More than 25% of polytraumatized patients present in the emergency department with a coagulopathy which results in a 4-fold increase in mortality. The detection of microvascular bleeding is the major clinical indicator. Measurement of fibrinogen, activated partial thromboplastin time and prothrombin time as well as thrombelastometry are required. A prerequisite for the substitution of coagulation factors and platelets is an immediate surgical control of bleeding and correction of hypothermia, acidosis and hypocalcemia. The goals for platelet count, fibrinogen, PT and aPTT are well established. The use of an algorithm for transfusion and coagulation management results in optimized therapy and improved outcome. Substituted coagulation products are only effective if hyperfibrinolysis has been corrected before. The administration of fibrinogen corrects the coagulation factor that is critically reduced earliest, improves global coagulation tests and reduced mortality in some studies. The dose required (3-5 g) can be calculated by a formula. Fresh frozen plasma is given in a 1:1 ratio to red blood cells or at least 20-40 ml/kg body weight. A clear advantage for survival has not yet been shown and some of the risks include insufficient substitution of fibrinogen and transfusion-related acute lung injury. Goals for the administration of platelet concentrates depend on the acuity of bleeding, injury pattern (e.g. head trauma) and clinical signs of microvascular bleeding. Factor VIIa remains an off-label rescue therapy if bleeding persists despite optimization of preconditions and specific coagulation management.
超过25%的多发伤患者在急诊科就诊时存在凝血病,这导致死亡率增加4倍。微血管出血的检测是主要临床指标。需要测定纤维蛋白原、活化部分凝血活酶时间和凝血酶原时间以及血栓弹力图。替代凝血因子和血小板的前提是立即进行手术控制出血并纠正体温过低、酸中毒和低钙血症。血小板计数、纤维蛋白原、PT和aPTT的目标已明确确立。使用输血和凝血管理算法可实现优化治疗并改善预后。只有在纠正了高纤维蛋白溶解后,替代凝血产品才有效。纤维蛋白原的给药可纠正最早严重降低的凝血因子,改善整体凝血试验,并在一些研究中降低死亡率。所需剂量(3 - 5 g)可通过公式计算。新鲜冰冻血浆与红细胞的输注比例为1:1,或至少按体重20 - 40 ml/kg给予。尚未显示出生存方面的明显优势,一些风险包括纤维蛋白原替代不足和输血相关急性肺损伤。血小板浓缩物的给药目标取决于出血的严重程度、损伤模式(如头部创伤)和微血管出血的临床体征。如果尽管优化了前提条件和进行了特定的凝血管理但出血仍持续,凝血因子VIIa仍是一种未获批准的挽救治疗方法。